Overview

A Study of [14C]GB491 in Male Healthy Subjects

Status:
Completed
Trial end date:
2022-11-14
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center study to evaluate the mass-balance and pharmacokinetics of GB491 in 4-8 healthy male subjects receiving a single oral 150mg dose of GB491 containing approximately 50 uCi of [14C]GB491. This study will help understand how the drug appears in the blood, urine, and feces after it is administered. In addition, this study will also evaluate the safety of a single dose of [14C]GB491 when given to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Genor Biopharma Co., Ltd.